BoomRay, Novartis sign $900m deal for radioligand therapy

BoomRay Pharmaceuticals and Novartis have signed an exclusive worldwide licence deal for an undisclosed preclinical RLT asset in a deal worth up to $900m. BoomRay focuses on radioligand therapies for precision oncology, spanning candidate discovery and clinical translation activities. The partnership brings together BoomRay’s development experience in RLTs and Novartis’s global presence in the field. Credit: Michael Derrer Fuchs / Shutterstock.com. China-based clinical-stage biotechnology company BoomRay Pharmaceuticals and Novartis have signed an exclusive worldwide licence deal for an undisclosed preclinical radioligand therapy (RLT) asset in a deal worth up to $900m. The agreement includes an upfront payment, as well as…

Salong Debbarma · 2026-09-23

BoomRay Pharmaceuticals and Novartis have signed an exclusive worldwide licence deal for an undisclosed preclinical RLT asset in a deal worth up to $900m.

Source: Pharmaceutical Technology